Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$86.59 USD

86.59
4,588,579

-1.00 (-1.14%)

Updated Nov 15, 2024 03:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio

by Zacks Equity Research

NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.

Here's Why You Should Buy Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard growth and raised guidance.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.

Acadia Healthcare (ACHC) Inks JV to Better Serve New Hampshire

by Zacks Equity Research

Acadia Healthcare (ACHC) enters into a JV with New Hampshire-based SolutionHealth to build a behavioral health facility and address the dire need for advanced behavioral health services across the state.

Quest Diagnostics (DGX) Presents New Data on Disease Testing

by Zacks Equity Research

Quest Diagnostics (DGX) is dedicated to create cutting-edge laboratory tests to help assess patient risk for dementia and other degenerative diseases.

Here's Why You Should Invest in Neogen (NEOG) Stock Now

by Zacks Equity Research

Investors are upbeat about Neogen (NEOG) owing to strong performance across its Animal Safety and Food Safety segments.

Baxter's (BAX) New Launch to Support Complex Critical Care Needs

by Zacks Equity Research

Baxter's (BAX) Progressa+ bed for the ICU is expected to enhance workflow and reduce strain on nursing resources.

Thermo Fisher's (TMO) New Launch to Advance Cancer Therapies

by Zacks Equity Research

Thermo Fisher's (TMO) Gibco OncoPro Tumoroid Culture Medium Kit is intended to increase researchers' access to sophisticated cancer models.

Walgreens (WBA) to Advance Diabetes Care at FFL Conference

by Zacks Equity Research

Walgreens (WBA) will sponsor Children with Diabetes' FFL event to make a difference in the lives of the 122 million individuals afflicted by diabetes and pre-diabetes.

Three Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Amedisys (AMED) to Advance Value-Based Care With Optum Merger

by Zacks Equity Research

Amedisys' (AMED) combination with Optum brings together two organizations committed to offering patients and their families compassionate, value-based comprehensive care.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) backed by the acquisition of Oak Street Health, which broadens its value-based primary care platform.

McKesson's (MCK) Latest Launch to Give Access to OTC Products

by Zacks Equity Research

McKesson's (MCK) latest launch is expected to meet the evolving needs and growing demand for quality OTC private-label health and wellness products.

Three Reasons to Add Masimo (MASI) Stock to Your Portfolio

by Zacks Equity Research

Masimo's (MASI) solid product suite raises optimism about the stock.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) on continued growth in Diabetes business and upbeat guidance.

Inspire Medical (INSP) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Inspire Medical's (INSP) global presence.

Masimo's (MASI) W1 to Boost Virtual Care in Preoperative Patients

by Zacks Equity Research

Masimo's (MASI) W1 advanced health-tracking watch is expected to provide better insights into pre-operative patients' heart rate variability data and improve pre-habilitation.

Abbott (ABT) FreeStyle Libre 2 Gets Reimbursement in France

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre increased reimbursement makes it possible for more people in France with diabetes to use the recent CGM technology.

Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its product innovation aiding growth.

Boston Scientific's (BSX) New Launches Aid Amid Cost Pressure

by Zacks Equity Research

Boston Scientific (BSX) remains excited about the rest of 2023 and expects to continue to outpace its peers within the EMEA market.

Here's How Much a $1000 Investment in Boston Scientific Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

The Zacks Analyst Blog Highlights Pfizer, Philip Morris, American Tower, Boston Scientific and Northrop Grumman

by Zacks Equity Research

Pfizer, Philip Morris, American Tower, Boston Scientific and Northrop Grumman are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Pfizer, Philip Morris & American Tower

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Philip Morris International Inc. (PM) and American Tower Corporation (AMT).

Quest Diagnostics' (DGX) New Buyout Expands Cancer Portfolio

by Zacks Equity Research

Quest Diagnostics (DGX) will use MRD technology to create new blood-based clinical lab services for solid tumour cancers that will be available starting in 2024.